At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.
ReachMD
Be part of the knowledge.™We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
The Itch Clinic: Treatment of Chronic Kidney Disease-Associated Pruritus in Hemodialysis Patients – Real-World Cases
Tune into this LIVE broadcast to hear real-world cases on the treatment of chronic kidney disease-associated pruritus in hemodialysis patients.
Overview
Disclosure of Conflicts of Interest
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.Faculty
Dr. Fishbane has disclosed the following relevant financial relationships:
Consultant and Researcher: Cara Therapeutics
Dr. Shirazian has disclosed the following relevant financial relationships:
Advisor: Vifor
Consultant: CARA
Speaker: Otsuka, Vifor
Jennifer Caudle, DO, Host: has no financial relationships to disclose.AKH Staff and Planners
Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
Michele Bielarski, RN - Nurse Reviewer: has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.Target Audience
This educational program will address identified educational and practice gaps among nephrology healthcare providers – physicians, nurses, nurse practitioners (NPs), physician assistants (PAs), and dieticians who care for patients with chronic kidney disease-associated pruritus (CKD-aP).
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Review the epidemiology of chronic kidney disease-associated pruritus (CKD-aP)
- Discuss pathophysiology and pathways associated with chronic kidney disease-associated pruritus (CKD-aP)
- Review the clinical trial data on emerging treatments for chronic kidney disease-associated pruritus (CKD-aP)
Accreditation and Credit Designation Statements
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
0.5 ANCC contact hoursPhysician Assistants
APA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.Dietitians
Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.5 contact hour(s) (which includes 0 hour(s) of pharmacology).Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.Criteria for Success
To receive credit, participants should review the entire activity, complete and submit posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.Provider(s)/Educational Partner(s)
Commercial Support
Supported by an educational grant from VIFOR PHARMA, INC.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Overview
At least 25% of patients with chronic kidney disease (CKD), and between 50% to 86% of patients with CKD on dialysis suffer from CKD-associated pruritus (CKD-aP). The itch can substantially interfere with sleep and quality of life and has been linked with depression, fatigue, and isolation. There are at least 4 pathways that have been hypothesized as possible etiologies of CKD-aP, leading to a wide range of potential therapeutic strategies for the itch. Difelikefalin is the first agent FDA-approved specifically for the treatment of moderate-to-severe pruritus in CKD patients undergoing dialysis; it is a peripheral kappa-opioid receptor agonist that targets the opioid dysregulation theory. It is imperative that all clinicians involved in the care of patients with CKD routinely inquire about pruritus and adequately treat their patients for CKD-aP. This case-based program will apply the foundational information presented in the first program of this 2-part series to real-world patients.
Disclosure of Conflicts of Interest
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.Faculty
Dr. Fishbane has disclosed the following relevant financial relationships:
Consultant and Researcher: Cara Therapeutics
Dr. Shirazian has disclosed the following relevant financial relationships:
Advisor: Vifor
Consultant: CARA
Speaker: Otsuka, Vifor
Jennifer Caudle, DO, Host: has no financial relationships to disclose.AKH Staff and Planners
Lynne Kolton Schneider, PhD, Medical Writer/Interviewer: has no financial relationships to disclose.
Dorothy Caputo, MA, BSN, RN, AKH Director of Accreditation, Planner: has no financial relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C, Nurse Planner/Reviewer: has no financial relationships to disclose.
Michele Bielarski, RN - Nurse Reviewer: has no financial relationships to disclose.
Patricia Brignoni, AKH Director of Operations: has no financial relationships to disclose.
Steve Eckert, AKH President & CEO, Planner: has no financial relationships to disclose.
All of the relevant financial relationships listed for these individuals have been mitigated.Target Audience
This educational program will address identified educational and practice gaps among nephrology healthcare providers – physicians, nurses, nurse practitioners (NPs), physician assistants (PAs), and dieticians who care for patients with chronic kidney disease-associated pruritus (CKD-aP).
Learning Objectives
Upon completion of the educational activity, participants should be able to:
- Review the epidemiology of chronic kidney disease-associated pruritus (CKD-aP)
- Discuss pathophysiology and pathways associated with chronic kidney disease-associated pruritus (CKD-aP)
- Review the clinical trial data on emerging treatments for chronic kidney disease-associated pruritus (CKD-aP)
Accreditation and Credit Designation Statements
Credit provided by AKH Inc., Advancing Knowledge in HealthcareIn support of improving patient care, AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Nurses
0.5 ANCC contact hoursPhysician Assistants
APA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.Dietitians
Nurse Practitioners
AKH Inc., Advancing Knowledge in Healthcare is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 030083. This activity is approved for 0.5 contact hour(s) (which includes 0 hour(s) of pharmacology).Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.Criteria for Success
To receive credit, participants should review the entire activity, complete and submit posttest and an evaluation. A certificate will be available upon successful completion of the quiz and evaluation. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this CE activity, please contact AKH Inc. at tbrignoni@akhcme.com.Provider(s)/Educational Partner(s)
Commercial Support
Supported by an educational grant from VIFOR PHARMA, INC.
System Requirements
Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.
Facebook Comments